Obsidian Therapeutics’ Paul Wotton, Ph.D., reveals what precipitated the FDA's clearance of its IND application for a novel, engineered, tumor-infiltrating lymphocyte therapy called OBX-115. Learn how the company navigated the regulatory path for a first-of-its-kind biologic therapy developed in partnership with the University of Texas MD Anderson Cancer Center that, should it succeed, will eliminate the patient risk associated with concomitant IL2 therapy and improve clinical outcomes for certain patients with metastatic melanoma. Listen now.
Following several mergers and acquisitions, a biopharmaceutical company had to manage an increasing amount of data from disparate online and offline sources. A solution allowed them to access data from various sources and to feed other systems with data quickly to support the company’s digital science and manufacturing informatics strategies.